Survivin is overexpressed in various types of tumors with the frequency of 34.5% in gastric cancers (25), 50–60% in colorectal cancers (25,26), 64% in malignant gliomas (27), 53–72% in lung cancers (28,29), and 70.7% in breast cancers (30). Here, BIRC5 is linked to malignant glioma.